AAIC 2025 Abstract
CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease
By Madison I. J. Honey, Yanaika Sylvana Hok-A-Hin, Elisabeth H. Thijssen, Show 9 more authorsCharlotte Elisabeth Teunissen
Study in peopleBiomarkers
Abstract
Background: Post‐translational modifications of tau, such as acetylation, are emerging as key mechanisms in tau pathology. Tau acetylation at lysine 174 (AcTau174) is elevated in primary neurons with frontotemporal dementia (FTD)‐linked mutations and in early Alzheimer’s disease (AD) brain tissue.
